Australia offers significant opportunities for international medical technology and healthcare companies. However, successful market entry requires a clear understanding of where demand exists, how purchasing decisions are made and whether the potential revenue justifies the investment.
According to the Australian Institute of Health and Welfare (AIHW), Australia spent A$290.7 billion on healthcare in 2024–25, equivalent to approximately 10.5% of GDP. Hospital expenditure reached A$123.4billion,while primaryhealthcareaccountedforafurtherA93 billion.
These figures demonstrate the scale of Australia's healthcare sector, but total expenditure is not the addressable market for any particular product. International manufacturers need to establish who their customers are, what influences their purchasing decisions and whether their technology offers a compelling alternative to existing solutions.
At Dearin & Associates, we help businesses evaluate international opportunities and develop commercially viable expansion strategies. For healthcare companies considering Australia, we recommend examining six issues before committing substantial resources.
1. Understand Where the Real Opportunities Are
Australia's healthcare system comprises public and private hospitals, specialist clinics, primary healthcare providers and community care organisations, each with different funding and purchasing arrangements.
For medical device manufacturers, understanding these distinctions is particularly important. In 2024–25, Australia recorded approximately 2.6 million elective hospitalisations involving surgery, of which 67% took place in private hospitals, according to AIHW hospital activity data.
For a manufacturer of surgical equipment or implants, this could make the private hospital sector an important target. However, the right entry point depends on where relevant procedures are performed, who controls purchasing decisions and how the product compares with existing alternatives.
The same principle applies to other healthcare segments. Substantial spending on cancer, cardiovascular disease and musculoskeletal conditions may indicate areas worth investigating, but expenditure alone does not establish unmet demand or commercial opportunity.
What About New Zealand?
Australia and New Zealand can offer complementary opportunities, particularly where a distributor operates across both markets. However, their procurement and regulatory systems differ.
New Zealand's Pharmac plays a central role in public hospital medical device contracting. As of January 2025, its contracts covered more than 170,000 medical devices from almost 150 suppliers, representing approximately 70% of public hospital medical device expenditure.
Manufacturers considering both countries should therefore assess their market-access strategies separately, even where a common distributor or commercial infrastructure may be appropriate.
2. Don't Confuse Market Interest With Market Demand
Success in the US, Europe or Asia does not guarantee demand in Australia. Healthcare organisations may have different purchasing requirements, funding constraints and established supplier relationships.
Similarly, an interested distributor does not necessarily indicate a viable market opportunity. A distributor may be willing to add an innovative product to its portfolio without having the resources or customer demand required to generate meaningful sales.
Consider a hypothetical European medical technology manufacturer that appoints an Australian distributor and forecasts strong first-year revenue. The product requires clinical demonstrations, training and technical support, but neither party has adequately budgeted for these activities.
Six months later, the distributor has generated interest but few orders. The underlying problem may be that the manufacturer underestimated the resources required to convert market access into customer adoption.
Before committing significant capital, manufacturers should test their assumptions with potential customers, clinicians, distributors and other relevant stakeholders. This provides a more reliable basis for investment decisions than market statistics or encouraging initial conversations alone.
3. Choose Your Distribution Model Carefully
International healthcare companies typically have three broad options for entering Australia:
● Appoint a distributor: Gain access to established customer relationships and local infrastructure, while accepting less direct control over sales and market development.
● Establish a local presence: Retain greater control over customer relationships and commercial strategy, but incur higher operating costs.
● Use local representation: Engage a local commercial partner to develop relationships and validate demand before establishing a larger operation.
The appropriate model depends on the product, its customers and the support required. A healthcare consumable may suit a conventional distributor, while complex medical technology requiring clinician training and technical support may need a more involved arrangement.
The Regulatory Sponsor Decision
One Australian-specific issue manufacturers should consider carefully is who will act as the regulatory sponsor.
For most medical devices supplied in Australia, an Australian-based legal entity must act as sponsor and meet the applicable Therapeutic Goods Administration (TGA) requirements. This might be the manufacturer's Australian subsidiary, its distributor or an independent regulatory sponsor. The choice has important commercial implications.
Consider a manufacturer that appoints a distributor which also acts as its regulatory sponsor and holds the relevant entry in the Australian Register of Therapeutic Goods (ARTG). If the distributor subsequently underperforms, changing commercial partners may also require transferring regulatory sponsorship.
The TGA provides mechanisms for these transfers, but the process and contractual arrangements between the parties matter. An independent sponsor may offer greater flexibility by separating regulatory responsibilities from distribution, although it involves additional costs.
Manufacturers should address sponsorship arrangements before signing a distribution agreement, including what happens if the relationship ends.
Understanding Distributor Margins
There is no universal gross margin for Australian healthcare distributors. Requirements vary according to product type and whether the distributor provides warehousing, sales, clinical training, technical support or other services.
Consider a hypothetical medical device selling for A$ 10,000, excluding GST.If the distributor requires a 35% gross margin, it retains A$3,500 in gross profit, leaving A$6,500 available to pay for the product. The manufacturer must still cover its own production, logistics and other costs.
This illustrates why companies should work backwards from the customer's acceptable price to determine whether the distribution model is commercially sustainable.
A distributor charging a higher margin but actively developing the market may offer greater value than one charging less while providing minimal support. The appropriate partner is the one whose capabilities, incentives and financial expectations align with the manufacturer's strategy.
4. Regulatory Approval Doesn't Guarantee Sales
Medical device manufacturers entering Australia must understand three distinct requirements:
● Regulatory authorisation: Can the product legally be supplied in Australia?
● Funding and reimbursement: How will customers pay for the product or associated treatment?
● Procurement and adoption: Who will evaluate, purchase and use the product?
Most medical devices must be included in the ARTG before supply, unless an exemption applies. However, meeting regulatory requirements does not guarantee that healthcare organisations will purchase the product.
The Prescribed List Example
Australia's private health insurance Prescribed List includes more than 11,000 medical devices and human tissue products, including certain joint replacements, pacemakers, cardiac stents and insulin pumps.
Eligible products used in qualifying hospital treatment attract specified private health insurance benefits. However, not every medical device qualifies, and inclusion does not guarantee that hospitals or clinicians will select a particular manufacturer's product. A diagnostic technology manufacturer, for example, may face different reimbursement and purchasing arrangements from a manufacturer of an eligible implantable cardiac device.
Manufacturers must therefore map the complete purchasing pathway, including clinical evaluation, procurement requirements, budget approval and reimbursement where relevant. Understanding how customers make purchasing decisions is as important as establishing that a product can legally be supplied.
5. Make Your Business Attractive to Australian Partners
Australian distributors assess more than the quality of a manufacturer's product. They also consider whether the business offers a commercially attractive, sustainable relationship. Manufacturers should be prepared to demonstrate:
● Product differentiation: A clear customer problem and a credible advantage over competing solutions.
● Evidence and market traction: Clinical, technical or commercial evidence supporting the product's claims.
● Commercial viability: Realistic pricing, sustainable margins and sufficient potential demand.
● Operational capability: Reliable supply, quality assurance and appropriate technical support.
● Management commitment: Willingness to invest in market development and support the distributor.
Manufacturers should apply equally rigorous standards when evaluating distributors. Customer relationships, competing product lines, sales capabilities and commitment to developing demand are all relevant considerations.
Exclusivity requires particular attention. Where a distributor seeks exclusive rights, the parties should agree on appropriate commercial commitments, performance expectations and review mechanisms. A successful distribution relationship depends on aligned interests and clear responsibilities. Both parties need to understand what they will contribute and how success will be measured.
6. Test the Market Before Committing: A Practical 90-Day Framework
A structured validation process can help international healthcare companies assess the Australian opportunity before making substantial investments.
At Dearin & Associates, we recommend an evidence-led approach that tests commercial assumptions and produces a clear investment decision. A practical starting point is a 90-day framework organised into three phases.
Days 1–30: Understand the Opportunity
Identify the relevant customer segments, market size, competitors, regulatory requirements, reimbursement considerations and likely routes to market.
The objective is to understand where a commercially attractive opportunity might exist and identify the assumptions requiring further validation.
Days 31–60: Validate Commercial Demand
Engage directly with potential customers, clinicians, distributors, procurement specialists and other relevant stakeholders.
Test customer interest, pricing assumptions, barriers to adoption, partner capabilities and the feasibility of different market-entry models. These conversations should distinguish genuine commercial demand from encouraging but non-committal interest.
Days 61–90: Build the Business Case
Consolidate the findings into a commercial assessment covering:
● Evidence of demand and achievable market opportunity.
● Distribution and market-entry options.
● Regulatory requirements and likely timelines.
● Pricing, margins and operating costs.
● Potential partners and their capabilities.
● Financial and operational risks.
Management can then decide whether to proceed, undertake further validation, modify the entry strategy or defer investment.
The 90-day timeframe is a commercial validation framework, rather than a guarantee that regulatory approvals, procurement contracts or a full market launch can be completed within three months.
The objective is to make an informed investment decision before committing significant resources. Identifying an unattractive opportunity early can be just as valuable as confirming a promising market.
The Bottom Line
Australia offers substantial opportunities for international healthcare and medical technology companies, supported by significant healthcare expenditure and established public and private healthcare markets.
However, successful market entry requires evidence of customer demand, an appropriate route to market, an understanding of regulatory and purchasing requirements, and a commercially sustainable operating model.
For international manufacturers, the central question is whether Australia is the right market for their product, business and stage of expansion. Answering that question before committing significant capital can make an important difference to the outcome.
About Dearin & Associates
Dearin & Associates is an international business consultancy helping companies expand into new markets, build commercial partnerships and grow across borders. Our services include market intelligence, international growth strategy, partner and distributor identification, market-entry planning and execution.
We combine commercial analysis with practical market-entry support to help companies make informed expansion decisions and implement their strategies.
Considering expansion into Australia or New Zealand?
If your company is exploring the Australian healthcare market, we can help you evaluate the opportunity, identify potential partners and develop a commercially viable entry strategy. Book an Australia Opportunity Scan, a 15-minute conversation to pressure-test the opportunity and your next move.
